Clearmind & Yissum Patent Psychedelic Compounds
Ticker: CMND · Form: 6-K · Filed: Aug 16, 2024 · CIK: 1892500
Sentiment: neutral
Topics: patent, collaboration, psychedelics, mental-health
TL;DR
Clearmind Medicine inks new international patent for next-gen psychedelics with Yissum.
AI Summary
Clearmind Medicine Inc. announced on August 16, 2024, an expansion of its collaboration with Yissum, the technology transfer company of The Hebrew University of Jerusalem. This expansion includes an international patent application for their Generation 3.0 psychedelic compounds, aimed at treating mental disorders.
Why It Matters
This patent filing could strengthen Clearmind Medicine's intellectual property portfolio in the developing psychedelic therapeutics market, potentially leading to future drug development and commercialization.
Risk Assessment
Risk Level: medium — The company is in the early stages of drug development, and patent approvals and market success are not guaranteed.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- Yissum (company) — Collaborator
- The Hebrew University of Jerusalem (company) — Affiliated institution of Yissum
- August 16, 2024 (date) — Press release date
FAQ
What is the specific focus of the international patent application filed by Clearmind Medicine and Yissum?
The international patent application focuses on Generation 3.0 psychedelic compounds designed for the treatment of mental disorders.
What is the significance of the collaboration between Clearmind Medicine and Yissum?
The collaboration is significant as it involves expanding their efforts to secure international patent protection for novel psychedelic compounds.
When was the press release regarding this patent application issued?
The press release was issued on August 16, 2024.
What type of issuer is Clearmind Medicine Inc. according to this filing?
Clearmind Medicine Inc. is filing as a Report of Foreign Private Issuer.
Which form does Clearmind Medicine Inc. indicate it files annually?
Clearmind Medicine Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 279 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-08-16 16:17:08
Filing Documents
- ea0211634-6k_clearmind.htm (6-K) — 12KB
- ea021163402ex99-1_clearmind.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-070256.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: August 16, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3